Modified HDL Particles for Low Attenuation Plaque Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for lipid-related conditions, particularly those involving low attenuation plaque, are inadequate in effectively reducing plaque burden and stabilizing or reversing the progression of associated diseases, as they primarily focus on alleviating symptoms rather than addressing the underlying lipid-related issues.
Innovation Solution
A method involving the selective removal of lipids from HDL particles to create modified HDL particles with increased pre-β HDL concentrations, which are administered to patients to delay, halt, or improve the progression of lipid-related conditions by reducing plaque burden through infusion therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for lipid-related conditions are used, then symptom alleviation is achieved, but plaque burden reduction and disease progression stabilization are inadequate
Solution Approach 1:
The patent extracts and removes lipids from HDL particles through a delipidation process, creating modified HDL particles with reduced lipid content. This extraction of harmful lipid components from the HDL particles enables them to more effectively reduce plaque burden and stabilize disease progression, directly addressing the inadequacy of current treatments.
Solution Approach 2:
The patent modifies the lipid content parameter of HDL particles by removing excess lipids through delipidation. This parameter change transforms conventional HDL into modified HDL with enhanced therapeutic properties, enabling superior plaque burden reduction and disease progression stabilization compared to current treatments.
2Reliability
If lipid removal from HDL is performed to create modified HDL particles, then plaque burden is reduced by 10-50%, but the treatment complexity increases
Solution Approach 1:
The patent performs delipidation of HDL particles in advance before administration to patients. This preliminary modification of HDL particles removes lipids and creates the therapeutic formulation beforehand, simplifying the actual treatment administration while achieving the 10-50% plaque burden reduction efficacy.
Solution Approach 2:
The patent uses modified HDL particles as an intermediary substance that mediates between the patient's lipid metabolism and plaque reduction goals. These pre-modified particles serve as the active therapeutic agent, reducing treatment complexity by consolidating the lipid removal function into a single administered product.
3Ease of operation
If conventional HDL is administered, then general lipid transport function is maintained, but low attenuation plaque reduction is insufficient
Solution Approach 1:
The patent changes the lipid content parameter of HDL particles through delipidation, creating modified HDL with enhanced plaque reduction capabilities. This parameter modification maintains the ease of administration while significantly improving low attenuation plaque reduction efficacy compared to conventional HDL.
Solution Approach 2:
The patent applies local quality modification by selectively removing lipids from specific regions of HDL particles. This creates modified HDL with non-uniform lipid distribution that enhances their ability to target and reduce low attenuation plaque while maintaining overall HDL function and administration simplicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively lowers low attenuation plaque by 10-50% and reduces overall plaque burden, stabilizing or improving the progression of diseases related to low attenuation plaque, as demonstrated by coronary CT angiogram scans.
Implementation Method 1
mixing the blood fraction with a lipid removing agent to yield a delipidated blood fraction
Data Source
AI summary
The present specification is directed to systems, apparatus and methods for delaying, halting and stabilizing, reversing, or improving the progression of at least one lipid-related condition. The progression of, stabilizing, or improving the at least one lipid-related condition is treated by determining if plaque is present in at least one artery of the patient and determining a type of plaque present in at least one artery of the patient. If a fibrous plaque is present, determining a treatment protocol based on Fractional Flow Reserve. If a low attenuation plaque is present, determining a treatment protocol based on plaque burden. Depending on the extent of plaque, the treatment protocol includes administering to the patient a high density lipoprotein composition derived from mixing a blood fraction with a lipid removing agent.